enGene Shares Rise 5% as Experimental Bladder Cancer Drug Responses Improve
Key Facts
enGene shares rose 5% in premarket trading on November 12 after the company announced updated results from a Phase 2 trial of its experimental bladder cancer treatment, according to Investing.com coverage. The move followed the release of data from the first pivotal cohort in the LEGEND trial, which is studying detalimogene voraplasmid in patients with high-risk non-muscle-invasive bladder cancer who did not respond to BCG treatment. The coverage reported that Piper Sandler upgraded the stock from "Neutral" to "Overweight" and set a price target of $4. enGene announced the results on November 11, after the market closed, and the shares ended that day at $1.8. The updated results put response measures and their durability at the center of the news, while the share move and analyst upgrade reflect the market's reaction in the following session.
The cohort included 125 patients, but the efficacy analysis was based on 120 patients eligible for evaluation as of the October 29, 2026 data cutoff, according to the company statement. The complete response rate at any time was 56% in the updated analysis, up from 54% in the April analysis. This measure means a patient achieved a complete response at some point during follow-up, while other measures track whether the response persists at specific time points. The company said the preliminary estimate of the probability that a response would last at least 12 months rose to 43% from 25% in the April analysis. The comparison pairs a more recent efficacy reading with earlier trial results, while remaining data from a single cohort within an ongoing Phase 2 trial.
The complete response rate at the 12-month mark improved to 24%, compared with 13% in the April analysis, according to the company. Median duration of response also increased to 10.1 months from 8.6 months in the previous analysis. The median is the point at which half of response durations are longer and half are shorter, so it differs from an estimate of the share of patients whose responses remain in place at a specific time point. The company said assessment of response durability was not complete for all participants as of the data cutoff. Nine patients were awaiting evaluation of response duration for at least 12 months, including 8 in the maintenance phase. These pending assessments remain part of the follow-up that will add information on response durability as the data mature.
Among other measures reported in the statement, disease had not progressed to muscle-invasive bladder cancer or a higher stage in 97% of patients eligible for efficacy evaluation, while 86% had not undergone cystectomy as of the data date. These percentages describe two different follow-up outcomes: disease progression on the one hand and cystectomy on the other. For safety, the company evaluated 125 patients and said 59% experienced at least one treatment-related adverse event. Most events were Grade 1 or 2, while serious treatment-related adverse events were reported in 2% of patients. The principal investigator of the LEGEND trial said, "The updated data are encouraging and show clinically meaningful antitumor activity with a favorable tolerability profile."
The next step is the regulatory process. enGene said it had agreed with the U.S. Food and Drug Administration on key elements of the biologics license application, including the patient population eligible for efficacy evaluation. The company expects to begin submitting the application before the end of 2026 and complete it in the first half of 2027. It also said an update on a cohort receiving the drug with a bladder irrigation solution containing a surfactant is expected in mid-2027. The company says potential FDA approval of the treatment could come in 2027, but that remains contingent on the regulatory review process. The drug has received the agency's Regenerative Medicine Advanced Therapy and Fast Track designations, which are intended to support the development and review of drugs for serious diseases and unmet medical needs and do not constitute marketing approval.
enGene says more than 75% of patients with high-risk non-muscle-invasive bladder cancer who do not respond to BCG receive care in community urology practices, and that it is preparing commercially to target this care setting. In financial context preceding the November announcement, the company disclosed in September that it had $266.3 million in cash, cash equivalents and marketable securities as of July 31, 2026. In an earlier disclosure, the company described an interim result for the pivotal cohort as a complete response in 54% of patients, with progression to muscle-invasive disease in 3.2%. The October analysis, which raised the complete response reading at any time to 56%, is part of a cumulative update to the trial results. The premarket share move and Piper Sandler upgrade were reported in coverage on November 12, while the $1.8 closing price was for the session on the previous day, when the company announced its results.